CT
CPRX

Clearstead Trust’s Catalyst Pharmaceutical CPRX Stock Holding History

Clearstead Trust’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-22
Closed -$434 – 1122
2025
Q3 		$434 Hold
22
– – ﹤0.01% 1397
2025
Q2 		$478 Buy
+22
New +$519 ﹤0.01% 1340

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Clearstead Trust's CPRX Position: Q4 2025 in Review

Clearstead Trust sold out of Catalyst Pharmaceutical (CPRX) in Q4 2025, closing a stake of 22 shares — an estimated $434 sold.

Clearstead Trust first reported a position in CPRX in Q2 2025 and held it in 2 quarters. The position peaked at $478 in Q2 2025. 373 funds tracked by Wall St. Rank hold CPRX as of Q4 2025.

  • Clearstead Trust reported no remaining Catalyst Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Clearstead Trust sold 22 Catalyst Pharmaceutical shares in Q4 2025, an estimated $434.
  • Clearstead Trust first reported a position in Catalyst Pharmaceutical in Q2 2025 and held it in 2 quarters.
  • Clearstead Trust's Catalyst Pharmaceutical position peaked at $478 in Q2 2025.
  • 373 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2025.

Based on Clearstead Trust's 13F filing for Q4 2025, filed 9 Feb 2026.